Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CLRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CLRB

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Cellectar Biosciences Inc

CLRB
Current price
4.97 USD -0.07 USD (-1.39%)
Last closed 5.04 USD
ISIN US15117F8077
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 14 399 481 USD
Yield for 12 month -93.70 %
1Y
3Y
5Y
10Y
15Y
CLRB
21.11.2021 - 28.11.2021

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

120.00 USD

P/E Ratio

Dividend Yield

Financials CLRB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CLRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-192 375 USD

Last Year

-192 375 USD

Current Quarter

Last Quarter

EBITDA -45 917 744 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -97.92 %
PEG Ratio
Return On Equity TTM -208.72 %
Wall Street Target Price 120.00 USD
Revenue TTM
Book Value 5.03 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -18.90 USD
Diluted Eps TTM -18.90 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CLRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -3.25
Price Book MRQ 1.84

Technical Indicators CLRB

For 52 Weeks

4.36 USD 94.50 USD
50 Day MA 8.14 USD
Shares Short Prior Month 2 061 526
200 Day MA 21.94 USD
Short Ratio 0.070
Shares Short 164 965
Short Percent 4.49 %